Skip to main content
. 2019 Dec 9;9:18575. doi: 10.1038/s41598-019-54960-y

Figure 2.

Figure 2

Identification and quantification of CTCs isolated from HCC patients. (A) Representative image of CTCs captured by the Labyrinth and stained using antibodies against Gly3, GS, Hep Par-1, CD45, and DAPI. Scale bar represents 10 μm. (B) Number of CTCs/mL in HCC patients grouped by TNM stage. **TNM stage 0-I vs non-HCC: p = 0.0019; ***stage II-IV vs non-HCC: p = 0.0001; stage 0-I vs II-IV, p = 0.1258 (ns). (C) CTC positivity rate in TNM stage. **non-HCC vs Stage 0-I: p = 0.0031; ***non-HCC vs Stage II-IV: p < 0.0001; *Stage 0-I vs II-IV: p = 0.0398. (D) CTC positivity rate in BCLC stage. **non-HCC vs Stage 0-A: p = 0.0048; ***non-HCC vs Stage B-C: p < 0.0001; Stage 0-A vs Stage B-C: p = 0.3126 (ns).